William Pickering
Stock Analyst at Bernstein
(1.66)
# 3,420
Out of 5,180 analysts
33
Total ratings
42.86%
Success rate
-3.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by William Pickering
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $90 → $94 | $57.24 | +64.22% | 6 | Feb 25, 2026 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $37 → $41 | $24.22 | +69.28% | 2 | Jan 21, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | n/a | $447.26 | - | 6 | Jan 12, 2026 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $94 | $74.45 | +26.26% | 1 | Dec 11, 2025 | |
| BHVN Biohaven | Downgrades: Market Perform | $34 → $9 | $9.62 | -6.44% | 3 | Nov 6, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $155 → $157 | $183.78 | -14.57% | 1 | Nov 3, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Market Perform | $14 → $15 | $13.27 | +9.27% | 2 | Oct 28, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $753 → $781 | $777.25 | +0.48% | 3 | Aug 27, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Market Perform | $13 | $22.13 | -41.26% | 1 | Jul 29, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $314 → $310 | $328.73 | -5.70% | 2 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $27 → $24 | $62.92 | -61.86% | 2 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $75.13 | - | 2 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $6 | $2.56 | +134.38% | 1 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $44 | $48.81 | -9.85% | 1 | Mar 21, 2023 |
BioMarin Pharmaceutical
Feb 25, 2026
Maintains: Outperform
Price Target: $90 → $94
Current: $57.24
Upside: +64.22%
Beam Therapeutics
Jan 21, 2026
Maintains: Outperform
Price Target: $37 → $41
Current: $24.22
Upside: +69.28%
Vertex Pharmaceuticals
Jan 12, 2026
Upgrades: Outperform
Price Target: n/a
Current: $447.26
Upside: -
BridgeBio Pharma
Dec 11, 2025
Initiates: Outperform
Price Target: $94
Current: $74.45
Upside: +26.26%
Biohaven
Nov 6, 2025
Downgrades: Market Perform
Price Target: $34 → $9
Current: $9.62
Upside: -6.44%
Biogen
Nov 3, 2025
Maintains: Market Perform
Price Target: $155 → $157
Current: $183.78
Upside: -14.57%
Intellia Therapeutics
Oct 28, 2025
Downgrades: Market Perform
Price Target: $14 → $15
Current: $13.27
Upside: +9.27%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Outperform
Price Target: $753 → $781
Current: $777.25
Upside: +0.48%
Sarepta Therapeutics
Jul 29, 2025
Initiates: Market Perform
Price Target: $13
Current: $22.13
Upside: -41.26%
Alnylam Pharmaceuticals
Jan 7, 2025
Maintains: Outperform
Price Target: $314 → $310
Current: $328.73
Upside: -5.70%
Nov 29, 2024
Maintains: Market Perform
Price Target: $27 → $24
Current: $62.92
Upside: -61.86%
Jun 14, 2024
Upgrades: Market Perform
Price Target: n/a
Current: $75.13
Upside: -
Mar 21, 2023
Initiates: Market Perform
Price Target: $6
Current: $2.56
Upside: +134.38%
Mar 21, 2023
Initiates: Market Perform
Price Target: $44
Current: $48.81
Upside: -9.85%